title: Current medication choices in juvenile rheumatoid arthritis II--update of a survey performed in 1993.
abstract: The documentation of treatments used for Juvenile Rheumatoid Arthritis (JRA) is important to allow for the evaluation of practice patterns for future outcome studies. A survey of nine pediatric rheumatologists was performed between September 1999 and February 2000. Each of the physicians prospectively recorded demographic and treatment information on consecutively sampled JRA patients (n=395). Pauciarticular onset JRA was present in 46%, polyarticular onset JRA in 35%, and systemic onset JRA in 19% of the children. Naproxen was the most frequently prescribed medication (55% of the patients), followed by methotrexate (MTX), which was used in 39% of the patients. Folic acid supplementation (1 mg/day) was provided to 69% of the patients treated with MTX. Etanercept was used in 11% of the children. Eleven percent of the patients received corticosteroids, and 13% of children on corticosteroids took calcium supplements. Uveitis was present in 8% and had a chronic course in 79% of those cases. Although systemic medications were used in 50% of the children with uveitis to control eye inflammation, severe damage to the eyes developed in 30% of them. Fourteen percent of the patients required gastroprotective medications. Compared with findings of a similar survey performed in 1993, there was no significant change in the frequency of use of naproxen, but nabumetone is now more often prescribed, and COX-2 inhibitors have been introduced in the therapy of JRA. Changes among second-line agents used for JRA have also occurred, although there was no change in the frequency of use of MTX or corticosteroids. JRA continues to be a treatment challenge for the practicing pediatric rheumatologist. Patients often show incomplete response to the currently available medications. Therefore, new therapeutic agents need to be evaluated for their use in JRA, and the treatment of JRA associated uveitis especially needs to be improved.
authors.affiliation: Children's Hospital Medical Center Cincinnati, Ohio 45229, USA. brus9z@chmcc.org
authors.forename: H I
authors.initials: HI
authors.lastname: Brunner
authors.forename: K N
authors.initials: KN
authors.lastname: Kim
authors.forename: S H
authors.initials: SH
authors.lastname: Ballinger
authors.forename: S L
authors.initials: SL
authors.lastname: Bowyer
authors.forename: T A
authors.initials: TA
authors.lastname: Griffin
authors.forename: G C
authors.initials: GC
authors.lastname: Higgins
authors.forename: R
authors.initials: R
authors.lastname: Mier
authors.forename: M H
authors.initials: MH
authors.lastname: Passo
authors.forename: R
authors.initials: R
authors.lastname: Rennebohm
authors.forename: K
authors.initials: K
authors.lastname: Schikler
authors.forename: D J
authors.initials: DJ
authors.lastname: Lovell